FDA Cites Facilities in China, Japan, and India Post author:Sam Post published:February 14, 2017 Post category:Drug Industry Daily The FDA issued warning letters to four overseas manufacturers over GMP and other failures. Source: Drug Industry Daily You Might Also Like Coherus Files PTAB Petition Against Amgen’s Enbrel August 15, 2017 Gilead’s Lenacapavir Deeply Suppresses HIV Load in Multidrug-Resistant Patients May 15, 2022 FDA Extends Electronic Submission Deadline for Type III Drug Master Files April 25, 2018